RxDoctor Payments Data

Arnold Stein, MD

Ophthalmology · Woodmere, NYNPI 1437232865

Payments from drug & device makers

$2,268in general payments, 2019–2025

Across 13 payments — averaging $174.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$282
  • Aerie Pharmaceuticals, Inc.$263
  • Alcon$246
  • AbbVie$18

What the payments were for

  • Food & beverage$81036%
  • Other$1,45864%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,268 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$319,123
Medicare patients
1,174
Services billed
3,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost84$35,287
Travoprost193$28,090
RhopressaNetarsudil Mesylate71$27,506
VyzultaLatanoprostene Bunod86$26,491
Alphagan PBrimonidine Tartrate55$12,263
SimbrinzaBrinzolamide/Brimonidine Tart46$11,900
CombiganBrimonidine Tartrate/Timolol53$11,623
Brimonidine Tartrate114$11,145
Timolol Maleate231$7,630
RocklatanNetarsudil Mesylat/Latanoprost20$6,239
RestasisCyclosporine12$6,074
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat244$4,201
TafluprostTafluprost/Pf14$2,578
Latanoprost369$2,349
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$2,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$18$65,246204 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$263$33,74591 claims
AlconSimbrinza$246$11,90046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Woodmere

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →